The suppressive effect of dabrafenib, a therapeutic agent for metastatic melanoma, in IgE-mediated allergic inflammation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi Y.-A. | - |
dc.contributor.author | Lee S. | - |
dc.contributor.author | Choi J.K. | - |
dc.contributor.author | Kang B.-C. | - |
dc.contributor.author | Kim M.-J. | - |
dc.contributor.author | Dhakal H. | - |
dc.contributor.author | Kwon T.K. | - |
dc.contributor.author | Khang D. | - |
dc.contributor.author | Kim S.-H. | - |
dc.date.available | 2020-04-06T07:38:26Z | - |
dc.date.created | 2020-04-02 | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 1567-5769 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/26429 | - |
dc.description.abstract | The functional inhibition of mast cells, which serve as a key effector cells in allergic reactions may be a specific target for treating immunoglobulin (Ig)E-mediated allergic reactions, which occur in various allergic diseases including anaphylaxis, asthma, and atopic dermatitis. In this study, we demonstrated the effects of dabrafenib, a therapeutic agent used to treat metastatic melanoma, with a focus on mast cell activation and local cutaneous anaphylaxis. In two types of mast cells (RBL-2H3 and mouse bone marrow-derived mast cells), dabrafenib (0.01, 0.1, 1 μM) pretreatment significantly decreased IgE-induced degranulation, intracellular calcium influx, and the activity of intracellular signaling molecules, such as Lyn, Syk, Akt, and PLCγ. Dabrafenib ameliorated mRNA and protein expression levels of interleukin-4 and tumor necrosis factor-α by the reduction of nuclear localization of nuclear factor-κB and nuclear factor of activated T-cells. In passive cutaneous anaphylaxis, oral administration of dabrafenib (0.1, 1, 10 mg/kg) reduced local pigmentation and ear thickness in a dose-dependent manner. Taken together, these results suggest that dabrafenib is a therapeutic drug candidate that controls IgE-mediated allergic inflammatory diseases through suppression of mast cell activity. © 2020 Elsevier B.V. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Elsevier B.V. | - |
dc.relation.isPartOf | International Immunopharmacology | - |
dc.title | The suppressive effect of dabrafenib, a therapeutic agent for metastatic melanoma, in IgE-mediated allergic inflammation | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000535959000098 | - |
dc.identifier.doi | 10.1016/j.intimp.2020.106398 | - |
dc.identifier.bibliographicCitation | International Immunopharmacology, v.83 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85081647878 | - |
dc.citation.title | International Immunopharmacology | - |
dc.citation.volume | 83 | - |
dc.contributor.affiliatedAuthor | Khang D. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Dabrafenib | - |
dc.subject.keywordAuthor | Histamine | - |
dc.subject.keywordAuthor | IgE-mediated allergic inflammation | - |
dc.subject.keywordAuthor | IL-4 | - |
dc.subject.keywordAuthor | Mast cells | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.